On August 7th, Novo Nordisk released its 2024 H1 financial report. Its star product GLP-1 (glucagon like peptide-1) drug semaglutide sold for $13 billion and is expected to challenge the global drug king in 2024.
Expected to impact the 2024 global drug king oral version of semaglutide research results revealed, with a weight loss of 13.6% in one year
2024-11-17 11:15:01 Source：